共 50 条
- [41] Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR)JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Earl, H. M.Vallier, A.Hiller, L.Fenwick, N.Iddawela, M.Hughes-Davies, L.Provenzano, E.McAdam, K.Hickish, T.Caldas, C.
- [42] Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia - First Results Of a Randomized German-French Cooperative Phase III TrialBLOOD, 2013, 122 (21)Schweighofer, Carmen D.Cymbalista, FlorenceMueller, CarolinBusch, RaymondePorcher, RaphaelLangerbeins, PetraCazin, BrunoFink, Anna-MariaDreyfus, BrigitteIbach, StefanLepretre, StephaneFischer, KirstenVehling-Kaiser, UrsulaEichhorst, BarbaraBergmann, Manuela A.Stilgenbauer, StephanDoehner, HartmutLeblond, VeroniqueHallek, MichaelLevy, Vincent
- [43] Positronenemissionstomographie(PET)-geleitete Behandlung des Hodgkin-Lymphoms im frühen Stadium mit günstigen Risikofaktoren: Endresultate der internationalen randomisierten Phase-III-HD16-Studie der Deutschen Hodgkin-StudiengruppePositron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international randomized phase III HD16 trial conducted by the German Hodgkin Study GroupStrahlentherapie und Onkologie, 2020, 196 (4) : 414 - 415Carsten Nieder
- [44] Initial experience on the application of Deauville criteria to the End of Therapy PET in a multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Lymphoma (FOLL12)EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S181 - S182Versari, A.Chauvie, S.Guerra, L.Franceschetto, A.Peano, S.Storto, G.Dondi, A.Luminari, S.Federico, M.
- [45] A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trialEJC SUPPLEMENTS, 2009, 7 (02): : 324 - 324Hoff, P.Clarke, S.Cunningham, D.Van Cutsem, E.Moore, M.Schmoll, H. J.Tabernero, J.Mueller, B.De Gramont, A.
- [46] Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE studyTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16Zhang, QingyuanShen, KunweiSong, Chuan-guiOuyang, QuchangLiu, ZhenzhenLiu, QiangFeng, JifengChiu, Joanne W. Y.Tang, JinhaiJiang, ZefeiTseng, Ling-MingWang, XiaojiaYang, LiuQian, ChenxiShao, Zhimin
- [47] First-line Treatment for locally advanced or metastatic Urothelial Carcinoma: A randomized, double-blind Phase-III-Multicenter Study of adjuvant Nivolumab Therapy versus Placebo in Patients with invasive High-Risk Urothelial CarcinomaAKTUELLE UROLOGIE, 2018, 49 (04) : 308 - 309Rexer, H.Ohlmann, C. -H.Gschwend, J.
- [48] A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Goss, P. E.Barrios, C. H.Bell, R.Finkelstein, D.Iwata, H.Martin, M.Braun, A. H.Dansey, R. D.Coleman, R. E.
- [49] Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group GeltamoBLOOD, 2016, 128 (22)Gonzalez-Barca, EvaCarrillo-Cruz, EstrellaGrande, CarlosMartin, AlejandroCoronado, MonicaMontes-Moreno, SantiagoMercadal, SantiagoRoncero, Josep Mariade Oteyza, Jaime PerezNicolas, ConcepcionRodriguez-Salazar, Maria JoseSancho, Juan-ManuelPalomera, LuisLopez-Jimenez, JavierAlbo, CarmenPenalver, Francisco-JavierHernandez, Jose AngelLopez-Guillermo, ArmandoRamirez, Maria JoseJarque, IsidroBargay, JoanCanales, MiguelConde, EulogioCaballero, Dolores
- [50] Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung CancerCLINICAL LUNG CANCER, 2012, 13 (06) : 500 - 504Spigel, David R.Edelman, Martin J.Mok, TonyO'Byrne, KennethPaz-Ares, LuisYu, WeiRittweger, KarenThurm, Holger